tradingkey.logo

Arrowhead Pharmaceuticals Announces Interim Clinical Data On Rnai-Based Obesity Candidates

ReutersJan 6, 2026 12:47 PM

- Arrowhead Pharmaceuticals Inc ARWR.O:

  • ARROWHEAD PHARMACEUTICALS ANNOUNCES INTERIM CLINICAL DATA ON RNAI-BASED OBESITY CANDIDATES SHOWING WEIGHT LOSS IN OBESE PATIENTS WITH DIABETES AND IMPROVED MEASURES OF BODY COMPOSITION

  • ARROWHEAD PHARMACEUTICALS - ARO-INHBE WITH TIRZEPATIDE ACHIEVES -9.4% WEIGHT LOSS

  • ARROWHEAD PHARMACEUTICALS - ARO-INHBE MONOTHERAPY ACHIEVES -9.9% VISCERAL FAT REDUCTION

  • ARROWHEAD PHARMACEUTICALS - ARO-ALK7 ACHIEVES -88% REDUCTION IN ALK7 MRNA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI